Everything about and for the lab sector

Search
LABinsights.net

     

     

Stay on top of the news!

Stay informed!
Read our monthly newsletter.

Your address will never be given to third parties.
See our privacy policy.

12-04-2018

Verseon to present novel anticancer agents at AACR

Print version
Send per email
Tweet this item
Share on LinkedIn

Verseon will present its novel anticancer agents for multidrug resistant cancers next week

Fremont, Calif.—Verseon will present new preclinical studies of its anticancer drug candidates at the American Association for Cancer Research (AACR) annual meeting in Chicago next week. Verseon’s tubulin inhibitors are potent against a range of cancer cell lines and may be well-suited for the treatment of hematological and solid tumors resistant to existing chemotherapy agents.

While chemotherapy remains the first line of treatment against most cancers, many tumors develop resistance to chemotherapy agents over time, limiting their efficacy. Cancer cells commonly render drugs ineffective by triggering an overproduction of transport proteins that expel many chemicals, including chemotherapeutics. In addition, cells can become resistant to paclitaxel and vinorelbine, important tubulin-targeting chemotherapy drugs, by overexpression of β-III tubulin.

“Our preclinical data show that Verseon’s new class of tubulin inhibitors maintain their efficacy in a number of cancer cell lines that are resistant to many widely used chemotherapy agents,” said Dr. Mohan Sivaraja, Verseon’s Associate Director of Discovery Biology, who will present the studies at AACR. “The insensitivity of our compounds to the major efflux pumps and to the overexpression of β III tubulin are especially promising, since they could help us address the need for a more effective, precise therapy.”

Verseon’s tubulin inhibitors display good in vitro physicochemical properties as well as favorable in vivo pharmacokinetics. In addition to in vitro studies in drug-resistant cell lines, Dr. Sivaraja will also present first in vivo tolerability results.

Verseon’s full AACR poster abstract can be accessed here. Details of the presentation are as follows:
Poster title: Potent cell cycle inhibitors suitable for treatment of multidrug-resistant tumors
Session title: DNA Damage and Cell Cycle Regulation Experimental Therapeutics
Date: Tuesday Apr 17, 2018
Time: 1:00 PM - 5:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster Section 38

Verseon uses its innovative computer-driven drug discovery platform to generate new drug candidates for a variety of indications. This platform provides access to many more drug-like molecules than are available to conventional pharmaceutical companies. Verseon currently has active programs in anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

  Product news Placed: 12-04-2018       Views: 46x  

More information

Company information

 
 .
 .
 .